State Key Laboratory of Oral Diseases, National Clinical Research Center for Oral Diseases, Department of Head and Neck Oncology, West China Hospital of Stomatology, Sichuan University, Chengdu, China.
State Key Laboratory of Oral Diseases, National Clinical Research Center for Oral Diseases, Department of Comfort Care Dental Center, West China Hospital of Stomatology, Sichuan University, Chengdu, China.
J Hematol Oncol. 2021 Sep 3;14(1):136. doi: 10.1186/s13045-021-01141-y.
Extracellular vesicles (EVs) are cell-derived membrane structures enclosing proteins, lipids, RNAs, metabolites, growth factors, and cytokines. EVs have emerged as essential intercellular communication regulators in multiple physiological and pathological processes. Previous studies revealed that mesenchymal stem cells (MSCs) could either support or suppress tumor progression in different cancers by paracrine signaling via MSC-derived EVs. Evidence suggested that MSC-derived EVs could mimic their parental cells, possessing pro-tumor and anti-tumor effects, and inherent tumor tropism. Therefore, MSC-derived EVs can be a cell-free cancer treatment alternative. This review discusses different insights regarding MSC-derived EVs' roles in cancer treatment and summarizes bioengineered MSC-derived EVs' applications as safe and versatile anti-tumor agent delivery platforms. Meanwhile, current hurdles of moving MSC-derived EVs from bench to bedside are also discussed.
细胞外囊泡 (EVs) 是一种细胞来源的膜结构,其中包含蛋白质、脂质、RNA、代谢物、生长因子和细胞因子。EVs 在多种生理和病理过程中作为重要的细胞间通讯调节剂而出现。先前的研究表明,间充质干细胞 (MSCs) 通过 MSC 衍生的 EVs 的旁分泌信号,在不同的癌症中既可以支持也可以抑制肿瘤的进展。有证据表明,MSC 衍生的 EVs 可以模拟其亲本细胞,具有促肿瘤和抗肿瘤作用,并具有内在的肿瘤趋向性。因此,MSC 衍生的 EVs 可以作为一种无细胞的癌症治疗替代方法。本综述讨论了关于 MSC 衍生的 EVs 在癌症治疗中的作用的不同见解,并总结了生物工程 MSC 衍生的 EVs 作为安全且多功能的抗肿瘤药物递送平台的应用。同时,还讨论了将 MSC 衍生的 EVs 从实验室转移到临床应用的当前障碍。
J Hematol Oncol. 2021-9-3
Int J Mol Sci. 2021-6-20
Stem Cell Res Ther. 2019-11-28
Stem Cells Transl Med. 2019-5-2
Int J Nanomedicine. 2025-8-15
J Nanobiotechnology. 2025-8-20
Stem Cell Res Ther. 2025-8-5
Medicine (Baltimore). 2025-7-18
Nat Nanotechnol. 2021-7
Adv Mater. 2021-4
J Hematol Oncol. 2021-2-12
Theranostics. 2021
Adv Sci (Weinh). 2020-11-27